MARKET

SRPT

SRPT

Sarepta Therapeutics Inc
NASDAQ
21.52
+0.03
+0.14%
Pre Market: 21.62 +0.1 +0.47% 09:04 01/02 EST
OPEN
21.45
PREV CLOSE
21.49
HIGH
21.77
LOW
21.33
VOLUME
2.15K
TURNOVER
0
52 WEEK HIGH
129.84
52 WEEK LOW
10.42
MARKET CAP
2.26B
P/E (TTM)
-6.7512
1D
5D
1M
3M
1Y
5Y
1D
Sarepta Therapeutics Grants Equity Awards to New Hires Under Incentive Plan
Reuters · 12/31/2025 22:20
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 12/31/2025 16:20
Weekly Report: what happened at SRPT last week (1222-1226)?
Weekly Report · 12/29/2025 09:04
Silver Breaks Above $70, Novo Nordisk Soars 9% On Obesity Pill Approval: What's Moving Markets Wednesday?
Benzinga · 12/23/2025 18:18
Weekly Report: what happened at SRPT last week (1215-1219)?
Weekly Report · 12/22/2025 09:04
Have Insiders Sold Sarepta Therapeutics Shares Recently?
Simply Wall St · 12/20/2025 12:35
Sarepta Therapeutics Extends Debt Maturities with New Notes
TipRanks · 12/19/2025 22:03
Sarepta Therapeutics Swaps $291 Million in Convertible Notes for New 2030 Debt and Cash
Reuters · 12/19/2025 21:35
More
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.

Webull offers Sarepta Therapeutics Inc stock information, including NASDAQ: SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.